AXIM Biotechnologies, Inc. booked $39.5k in FY2023 revenue, growing 345% year over year — faster than 93% of Healthcare companies we track, at a -20395.0% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.